Alterations in Cell Motility, Proliferation, and Metabolism in Novel Models of Acquired Temozolomide Resistant Glioblastoma

Glioblastoma (GBM) is an aggressive and incurable tumor of the brain with limited treatment options. Current first-line standard of care is the DNA alkylating agent temozolomide (TMZ), but this treatment strategy adds only ~4 months to median survival due to the rapid development of resistance. Whil...

Descripción completa

Detalles Bibliográficos
Autores principales: Tiek, D. M., Rone, J. D., Graham, G. T., Pannkuk, E. L., Haddad, B. R., Riggins, R. B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5940876/
https://www.ncbi.nlm.nih.gov/pubmed/29740146
http://dx.doi.org/10.1038/s41598-018-25588-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5940876/
https://www.ncbi.nlm.nih.gov/pubmed/29740146
http://dx.doi.org/10.1038/s41598-018-25588-1

Ejemplares similares